Clinical Trial Detail

NCT ID NCT01456325
Title A Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Patients With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung)
Recruitment Completed
Gender both
Phase Phase III
Variant Requirements No
Sponsors Genentech
Indications

lung non-small cell carcinoma

Therapies

Erlotinib

Onartuzumab

Age Groups: adult senior

No variant requirements are available.